In June 2021, 23andMe completed their IPO with the VG Acquisition Corp, a special-purpose acquisition company. Due to the COVID-19 pandemic, there was more interest in genomics, as its value at scale had been demonstrated through many of the public health vaccine sequencing initiatives. Given these favorable market conditions and access to capital, was this the right time for 23andMe to shift their business model away from a consumer genetic testing company to a personalized health care company that collects genetic data to develop drugs and provide care? Did the company have the resources in place to achieve this vision? Could they do it alone or did they need to deepen their relationships with pharmaceutical companies, some of whom they were already in partnership with? In the age of growing consumer data privacy concerns, should Anne Wojcicki, 23andMe’s chief executive officer and co-founder be wary of this approach of collecting genetic data?

In June 2021, 23andMe completed their IPO with the VG Acquisition Corp, a special-purpose acquisition company. Due to the COVID-19 pandemic, there was more interest in genomics, as its value at scale had been demonstrated through many of the public health vaccine sequencing initiatives. Given these favorable market conditions and access to capital, was this the right time for 23andMe to shift their business model away from a consumer genetic testing company to a personalized health care company that collects genetic data to develop drugs and provide care? Did the company have the resources in place to achieve this vision? Could they do it alone or did they need to deepen their relationships with pharmaceutical companies, some of whom they were already in partnership with? In the age of growing consumer data privacy concerns, should Anne Wojcicki, 23andMe's chief executive officer and co-founder be wary of this approach of collecting genetic data?